Purchase this article with an account.
Christine Frances Wildsoet; Does low-dose atropine slow myopic eye elongation - Observations from humans?. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3295.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
The problem of significant, unacceptable ocular side-effects associated with the use of daily 1% topical ophthalmic atropine presents a substantial obstacle to its wide-spread adoption, despite reports of robust inhibitory effects on myopia progression in children. However, recent reports of slowed myopia progression with much lower concentrations, with fewer associated side-effects, has lead to a rapid increase in the use of daily topical 0.01% atropine off-label around the world. This presentation will consider the pharmacological rationale for this treatment strategy and against this background, review the evidence that it slows eye elongation (as opposed to reducing myopic refractions), the variability in its effect, its dose-dependence and potential sites of action, based on related clinical studies.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only